Published ahead of print on February 18, 2005, doi:10.1165/rcmb.2004-0287OC
Am. J. Respir. Cell Mol. Biol., Volume 32, Number 5, May 2005, 420-427
A more recent version of this article appeared on May 1, 2005
Submitted on September 13, 2004
Revised on February 18, 2005
VEGF Receptor 2 Blockade Disrupts Postnatal Lung Development
Sharon A McGrath-Morrow1*, Cecilia Cho1, Chung Cho2, Lijie Zhen2, Daniel J Hicklin3, and Rubin M Tuder4
1 Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA,
2 Division of Cardiopulmonary Pathology, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA,
3 Imclone Systems Incorporated, New York, NY, USA,
4 Division of Cardiopulmonary Pathology, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
* To whom correspondence should be addressed. E-mail: smorrow{at}jhmi.edu.
Vascular endothelial growth factor (VEGF) is necessary for normal postnatal lung development and may underlie the structural lung damage that follows hyperoxic exposure. To determine the individual roles of VEGF receptors (VEGFR) 2 and 1 on postnatal lung growth, neonatal mice were treated with neutralizing antibodies to VEGFR-2 (DC101) or VEGFR-1 (MF1) in the perinatal period. At one week of age, mice treated with DC101 on days two and four of life, had significantly larger mean alveolar diameters (MADs) consistent with impaired alveolization. By two weeks of age, however, perinatally treated DC101mice had normal appearing alveolar structure. Mice exposed to perinatal hyperoxia (O2) also had larger MADs at one week of age, but unlike DC101-treated mice, their mitotic index was decreased at one week of age and they had persistent alveolar enlargement beyond the first two weeks of life. The O2-treated lung also had an increase in caspase 3 at one week of age and significantly greater expression of nitrotyrosine at two weeks of age. Therefore VEGFR-2 blockade in the perinatal period disrupts early alveolar development but the effect is reversible with time, whereas hyperoxic lung injury is associated with ongoing lung structural impairment.
This article has been cited by other articles:

|
 |

|
 |
 
V. Bhandari, R. Choo-Wing, C. G. Lee, K. Yusuf, J. H. Nedrelow, N. Ambalavanan, H. Malkus, R. J. Homer, and J. A. Elias
Developmental Regulation of NO-Mediated VEGF-Induced Effects in the Lung
Am. J. Respir. Cell Mol. Biol.,
October 1, 2008;
39(4):
420 - 430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Boucherat, M.-L. Franco-Montoya, C. Thibault, R. Incitti, B. Chailley-Heu, C. Delacourt, and J. R. Bourbon
Gene expression profiling in lung fibroblasts reveals new players in alveolarization
Physiol Genomics,
December 19, 2007;
32(1):
128 - 141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Bland, L. M. Mokres, R. Ertsey, B. E. Jacobson, S. Jiang, M. Rabinovitch, L. Xu, E. S. Shinwell, F. Zhang, and M. A. Beasley
Mechanical ventilation with 40% oxygen reduces pulmonary expression of genes that regulate lung development and impairs alveolar septation in newborn mice
Am J Physiol Lung Cell Mol Physiol,
November 1, 2007;
293(5):
L1099 - L1110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-R. Tang, G. Seedorf, V. Balasubramaniam, A. Maxey, N. Markham, and S. H. Abman
Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor inhibition
Am J Physiol Lung Cell Mol Physiol,
November 1, 2007;
293(5):
L1271 - L1280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Bland, L. Xu, R. Ertsey, M. Rabinovitch, K. H. Albertine, K. A. Wynn, V. H. Kumar, R. M. Ryan, D. D. Swartz, K. Csiszar, et al.
Dysregulation of pulmonary elastin synthesis and assembly in preterm lambs with chronic lung disease
Am J Physiol Lung Cell Mol Physiol,
June 1, 2007;
292(6):
L1370 - L1384.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Yee, P. F. Vitiello, J. M. Roper, R. J. Staversky, T. W. Wright, S. A. McGrath-Morrow, W. M. Maniscalco, J. N. Finkelstein, and M. A. O'Reilly
Type II epithelial cells are critical target for hyperoxia-mediated impairment of postnatal lung development
Am J Physiol Lung Cell Mol Physiol,
November 1, 2006;
291(5):
L1101 - L1111.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Tuder, T. Yoshida, W. Arap, R. Pasqualini, and I. Petrache
State of the Art. Cellular and Molecular Mechanisms of Alveolar Destruction in Emphysema: An Evolutionary Perspective
Proceedings of the ATS,
August 1, 2006;
3(6):
503 - 510.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Shapiro
Extracellular matrix in lung disease. Proceedings of the Twenty-First Transatlantic Airway Conference.
Proceedings of the ATS,
July 1, 2006;
3(5):
397 - 455.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Petrache, I. Fijalkowska, L. Zhen, T. R. Medler, E. Brown, P. Cruz, K.-H. Choe, L. Taraseviciene-Stewart, R. Scerbavicius, L. Shapiro, et al.
A Novel Antiapoptotic Role for {alpha}1-Antitrypsin in the Prevention of Pulmonary Emphysema
Am. J. Respir. Crit. Care Med.,
June 1, 2006;
173(11):
1222 - 1228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. Stenmark and V. Balasubramaniam
Angiogenic Therapy for Bronchopulmonary Dysplasia: Rationale and Promise
Circulation,
October 18, 2005;
112(16):
2383 - 2385.
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 American Thoracic Society.
|
|
|